retatrutide triple agonist phase 2 obesity trial ⭐️topline results from TRIUMPH-1, a 3 clinical evaluating #retatrutide, an investigational GIP / GLP-1 / glucagon hormone receptor agonist, in adults with or “overweight” Retatrutide Explained: The Triple Agonist

With any injections, there may be redness, soreness and bruising at the injection site, bruising may last 5-7 days

Additionally, she underscores the need for tailored nutrition to support the body in the perimenopause and menopausal life stage

That same reactivity makes it profoundly unstable when exposed to its enemies: heat, light, and oxygen

Were seeing an increase in humanizing, compassionate portrayals of people in larger bodies in GLP-1 weight-loss advertising, meanwhile just the presence of GLP-1s is reinforcing the idea that fat bodies are something that need to be fixed, i.e., weight stigma

Patients can exhibit various neuropsychiatric signs and symptoms: confusion, sleep disruption, cognitive and intellectual dysfunction, impaired motor activity, slowed or slurred speech, and incoordination

The peptide has an important role in detoxifying reactions such as scavenging cellular hydrogen peroxide and conjugation of electrophilic metabolites of xenobiotics (Franco and Cidlowski, 2012)